The global bone growth stimulator market size is expected grow from USD 1.83 billion in 2021 to reach USD 2.55 billion by 2028, exhibiting a CAGR of 4.8% during the forecast period. The growing bone fractures and sports injuries around the world will promote the growth of the market in the forthcoming years, states Fortune Business Insights, in a report, titled “Bone Growth Stimulator Market, 2021-2028.” The market size stood at USD 1.75 billion in 2020.

Get Sample PDF Brochure: https://www.fortunebusinessinsights.com/enquiry/sample/bone-growth-stimulators-market-100161

Acquisition of Stimgenics by Medtronic to Consolidate Business

Stimgenics, LLC, a privately held business situated in Bloomington, Illinois, has pioneered a unique spinal cord stimulation (SCS) waveform known as Differential Target Multiplexed (DTMTM) Spinal Cord Stimulation, according to Medtronic plc. The treatment, which is provided through the Medtronic IntellisTM platform, is a novel programming option for treating chronic pain sufferers. The results of a three-month randomized control trial (RCT) comparing DTM to traditional SCS will be presented at the North American Neuromodulation Society (NANS) 23rd Annual Meeting in Las Vegas on January 23-26. The acquisition will create lucrative opportunities for the market. DTM waveform can activate a new mechanism that affects both neurons and glial cells, adding to our knowledge of SCS action mechanisms. When compared to either low frequency or high frequency alone, the DTM waveform has shown a statistically significant reversal of pain responses in animal models.

Introduction of Innovative Products by Major Brands to Foster Growth

Increasing efforts from various manufacturers to produce unique and creative technologically advanced items would help the sector grow considerably. For example, Bioventus LLC released EXOGEN, an ultrasonic bone healing stimulator system, in Saudi Arabia in March 2016. Non-unions, delayed unions, and joint fusion are all treated with this product. In February 2020, Orthofix announced that the STIM onTrack mobile app version 2.1 had been approved by the US Food and Drug Administration (FDA) for use with the Company’s bone growth stimulators.

For More Information : https://www.fortunebusinessinsights.com/industry-reports/bone-growth-stimulators-market-100161

About Us:

Fortune Business Insights™ delivers accurate data and innovative corporate analysis, helping organizations of all sizes make appropriate decisions. We tailor novel solutions for our clients, assisting them to address various challenges distinct to their businesses. Our aim is to empower them with holistic market intelligence, providing a granular overview of the market they are operating in.

Contact Us:

Fortune Business Insights™ Pvt. Ltd.

US :+1 424 253 0390

UK : +44 2071 939123

APAC : +91 744 740 1245

Email: sales@fortunebusinessinsights.com

Leave a Reply

Your email address will not be published. Required fields are marked *